Nuveen Asset Management, LLC Gossamer Bio, Inc. Transaction History

Nuveen Asset Management, LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$7.21 - $14.88 $2.52 Million - $5.21 Million	350,167 Added 214.0%	513,793 $6.16 Million
Q2 2022 Aug 15, 2022	SELL	$5.97 - $9.97 $240,650 - $401,890	-40,310 Reduced 19.77%	163,626 $1.37 Million
Q1 2022 May 16, 2022	SELL	$8.44 - $12.49 $25,471 - $37,694	-3,018 Reduced 1.46%	203,936 $1.78 Million
Q4 2021 Feb 14, 2022	SELL	$10.12 - $14.07 $151,850 - $211,120	-15,005 Reduced 6.76%	206,954 $2.13 Million
Q3 2021 Nov 12, 2021	SELL	$7.25 - $13.23 $46,313 - $84,513	-6,388 Reduced 2.8%	221,959 $2.34 Million
Q2 2021 Aug 16, 2021	SELL	$8.0 - $9.75 $5.73 Million - $6.98 Million	-715,947 Reduced 75.82%	228,347 $1.85 Million
Q1 2021 May 17, 2021	BUY	$8.63 - $10.94 $1.95 Million - $2.47 Million	226,078 Added 31.48%	944,294 $8.74 Million
Q4 2020 Feb 16, 2021	BUY	$8.3 - $13.59 $1.24 Million - $2.04 Million	149,796 Added 26.35%	718,216 $6.95 Million
Q3 2020 Nov 16, 2020	BUY	$11.3 - $14.75 $4.3 Million - $5.61 Million	380,130 Added 201.89%	568,420 $7.05 Million
Q2 2020 Aug 14, 2020	SELL	$9.52 - $15.98 $50,751 - $85,189	-5,331 Reduced 2.75%	188,290 $2.45 Million
Q1 2020 May 14, 2020	BUY	$8.0 - $15.48 $123,048 - $238,097	15,381 Added 8.63%	193,621 $1.97 Million
Q4 2019 Feb 14, 2020	BUY	$14.82 - $26.79 $111,846 - $202,184	7,547 Added 4.42%	178,240 $2.79 Million
Q3 2019 Nov 14, 2019	BUY	$16.02 - $22.47 $1.18 Million - $1.65 Million	73,624 Added 75.85%	170,693 $2.87 Million
Q2 2019 Aug 15, 2019	BUY	$16.12 - $22.89 $1.56 Million - $2.22 Million	97,069 New	97,069 $2.15 Million

109

167M

430K

519K

Ticker GOSS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,954,000
Market Cap $83.6M
Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.